Frederic T. BillingsIV

Frederic T. BillingsIV

Auto-generated profile, based on publicly available information

Frederic T. BillingsIV

Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in JAMA
Verified
Journal Article
Open access
PDF file
FBFrederic T. Billings
Frederic T. Billings
PHPatricia A. Hendricks
Patricia A. Hendricks
JSJonathan S. Schildcrout
Jonathan S. Schildcrout
YSYaping Shi
Yaping Shi
MPMichael R. Petracek
Michael R. Petracek
NBNancy J. Brown
Nancy J. Brown
Acute kidney injury (AKI) complicates recovery from cardiac surgery in up to 30% of patients.1 Surgical, anesthetic, and critical care advancements have reduced perioperative mortality but have not reduced the incidence of AKI, and some studies have reported increasing rates of postoperative dialysis.2-4 Recent large cohort studies confirm that even mild postoperative AKI is independently associated with a 5-fold increase in death while in the hospital.5 A diagnosis of AKI following cardiac surgery is accompanied by higher rates of postoperative arrhythmias, respiratory failure, systemic infection, and myocardial infarction.1,5-7 Treatments are needed to reduce this debilitating postoperative outcome.

1 July 2012 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
FBFrederic T. Billings
Frederic T. Billings
MPMias Pretorius
Mias Pretorius
JSJonathan S. Schildcrout
Jonathan S. Schildcrout
NMNathaniel D. Mercaldo
Nathaniel D. Mercaldo
JBJohn G. Byrne
John G. Byrne
NBNancy J. Brown
Nancy J. Brown
Obesity increases oxidative stress, endothelial dysfunction, and inflammation, but the effect of obesity on postoperative AKI is not known. We examined the relationship between body mass index (BMI) and AKI in 445 patients undergoing cardiac surgery and whether oxidative stress (F2-isoprostanes), inflammation (IL-6), or antifibrinolysis (plasminogen activator inhibitor-1 [PAI-1]) contribute to any identified relationship. Overall, 112 (25%) of the 445 patients developed AKI. Higher BMI was independently associated with increased odds of AKI (26.5% increase per 5 kg/m2 [95% confidence interval, 4.3%–53.4%]; P=0.02). Baseline F2-isoprostane (P=0.04), intraoperative F2-isoprostane (P=0.003), and intraoperative PAI-1 (P=0.04) concentrations also independently predicted AKI. BMI no longer predicted AKI after adjustment for the effect of F2-isoprostanes, suggesting that obesity may affect AKI via effects on oxidative stress. In contrast, adjustment for IL-6 or PAI-1 did not substantially alter the association between BMI and AKI. Further, deconstruction of the obesity-AKI relationship into direct (i.e., independent of candidate pathways) and indirect (i.e., effect of BMI on AKI via each candidate pathway) effects indicated that F2-isoprostanes, but not IL-6 or PAI-1, partially mediate the relationship between obesity and AKI (P=0.001). In conclusion, obesity independently predicts AKI after cardiac surgery, and oxidative stress may partially mediate this association.

1 February 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
MLMarcos G. Lopez
Marcos G. Lopez
PPPratik Pandharipande
Pratik Pandharipande
JMJennifer Morse
Jennifer Morse
MSMatthew S. Shotwell
Matthew S. Shotwell
GMGinger L. Milne
Ginger L. Milne
FBFrederic T. Billings
Frederic T. Billings

1 April 2019 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
JCJared J. Cummings
Jared J. Cummings
ASAndrew D. Shaw
Andrew D. Shaw
JSJing Shi
Jing Shi
MLMarcos G. Lopez
Marcos G. Lopez
JOJason B. O'NEal
Jason B. O'NEal
FBFrederic T. Billings
Frederic T. Billings

1 December 2010 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
FBFrederic T. Billings
Frederic T. Billings
MPMias Pretorius
Mias Pretorius
ESEdward D. Siew
Edward D. Siew
CYChang Yu
Chang Yu
NBNancy J. Brown
Nancy J. Brown

3 November 2015 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
CYCatherine K. Yeung
Catherine K. Yeung
FBFrederic T. Billings
Frederic T. Billings
ACAdam J. Claessens
Adam J. Claessens
BRBaback Roshanravan
Baback Roshanravan
LLLori Linke
Lori Linke
JHJonathan Himmelfarb
Jonathan Himmelfarb
Coenzyme Q10 (CoQ10) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ10 in chronic hemodialysis patients, a population subject to increased oxidative stress. We performed a dose escalation study to test the hypothesis that CoQ10 therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of F2-isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ10 concentrations were measured to determine dose, concentration and response relationships. Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ10 levels increased in a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study (P = 0.003 vs. baseline and P < 0.001 for the effect of dose escalation on isofurans). Plasma F2-isoprostane concentrations did not change during the study. CoQ10 supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ10 supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ10 supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis. This clinical trial was registered on clinicaltrials.gov [ NCT00908297 ] on May 21, 2009.